Welcome to our dedicated page for Labcorp Holdings SEC filings (Ticker: LH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Labcorp Holdings Inc. (NYSE: LH), a global provider of innovative and comprehensive laboratory services. These documents offer detailed information about the company’s operations, financial condition, governance and material events.
Labcorp’s recent current reports on Form 8-K include disclosures about quarterly and annual financial results, updated guidance and capital allocation decisions such as cash dividends on its common stock. Other 8-K filings describe participation in investor conferences, appointments and retirements of directors and executives, and transactions affecting parts of its business, such as the sale of select early development medical device testing assets.
Filings also confirm that Labcorp’s common stock, with a par value of $0.10 per share, is registered under Section 12(b) of the Securities Exchange Act and trades on the New York Stock Exchange under the symbol LH. Segment information released through earnings-related filings outlines performance for the Diagnostics Laboratories and Biopharma Laboratory Services segments, providing context on demand for clinical testing and biopharma laboratory services.
On Stock Titan, Labcorp’s SEC filings are updated as they become available from EDGAR. AI-powered summaries help explain the key points in complex documents, so readers can quickly understand items such as results of operations, changes in leadership, dividend declarations and significant transactions. Users can review Forms 8-K for material events, as well as other core filings like annual reports on Form 10-K, quarterly reports on Form 10-Q and proxy materials when they are filed.
For investors, analysts and other interested readers, this page serves as a focused entry point into Labcorp’s regulatory disclosures, combining real-time updates with AI-generated highlights to make the information easier to interpret.
LABCORP HOLDINGS INC. executive Sandra D. van der Vaart, EVP, Corporate Affairs, received a grant of 6,382 shares of common stock on March 26, 2026. The award was earned under a performance plan covering the three-year period ended December 31, 2025.
To cover tax withholding obligations on this award, 2,722 shares were withheld at a price of $268.38 per share, rather than sold in the open market. After these transactions, she directly holds 6,238.9467 shares of Labcorp common stock.
LABCORP HOLDINGS INC. executive Amy B. Summy received 3,994 shares of common stock on March 26, 2026, as a performance award tied to the three-year period ended December 31, 2025. To cover tax obligations, 1,836 shares were withheld at $268.38 per share, leaving her with 7,879.5 shares held directly after these transactions.
Labcorp Holdings EVP, CIO & CTO Akinbolade Oyegunwa received 1,340 shares of common stock as a performance-based award. The award relates to company performance over the three-year period ending December 31, 2025. On the same date, 382 shares were withheld at $268.38 per share to satisfy tax withholding obligations, resulting in a net increase in holdings. After these transactions, Oyegunwa directly owns 5,064.253 shares of Labcorp common stock.
LABCORP HOLDINGS INC. executive vice president of operations Jonathan C. Meltzer reported a mix of equity compensation and routine share sales. On March 26, 2026, he acquired 2,388 shares of common stock at no cost through a performance award tied to results for the three-year period ended December 31, 2025. That same day, 711 shares were withheld to cover tax obligations. On March 27, 2026, he conducted an open-market sale of 839 shares at $267.05 per share under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly holds 3,620.3256 shares of Labcorp common stock.
LABCORP HOLDINGS INC. executive Kathryn W. Kyle, EVP and Chief Legal Officer, received a grant of 1,584 shares of common stock on March 26, 2026 pursuant to a performance award tied to a three-year period ending December 31, 2025. To cover tax withholding obligations, 451 shares were disposed of through stock withholding at $268.38 per share, leaving her with 4,575.4574 shares of common stock held directly after these transactions. These events reflect compensation-related share awards and associated tax withholding rather than open-market trading.
LABCORP HOLDINGS INC. executive Megan D. Bailey received an award of 1,184 shares of common stock on March 26, 2026, as part of a performance award granted on February 7, 2023 for a three-year period ending December 31, 2025. To cover tax withholding obligations, 481 shares were withheld at a price of $268.38 per share, leaving her with 4,851 shares of common stock held directly after these transactions. These movements reflect compensation-related equity awards and associated tax withholding rather than open-market trading.
LH reported insider sales by Jonathan Meltzer. The filing lists three dispositions in February 2026: 88 shares on 02/09/2026 for $24,246.64, 91 shares on 02/10/2026 for $25,187.89, and 87 shares on 02/12/2026 for $25,266.54. The excerpt also shows a restricted stock vesting event dated 03/26/2026.
The Vanguard Group filed an amendment to Schedule 13G reporting that it beneficially owns 0 shares of Labcorp Holdings Inc Common Stock and holds 0% of the class. The filing explains an internal realignment effective January 12, 2026, under SEC Release No. 34-39538 that caused certain subsidiaries or business divisions to report disaggregated ownership separately from The Vanguard Group.
The form states The Vanguard Group and its managed accounts have the right to receive dividends or proceeds for the securities reported, and no single other person holds more than 5% of the class according to the filing. The submission is signed by the Head of Global Fund Administration on 03/26/2026.
Labcorp Holdings Inc. entered into a new Credit Agreement providing a $750,000,000 senior unsecured term loan maturing on March 20, 2028. The loan was fully funded at closing and bears floating interest at either a SOFR-based rate plus a 0.700% margin or a base rate plus a 0% margin.
The agreement includes customary covenants limiting additional subsidiary debt, liens, mergers, and major asset sales, along with standard events of default. It also requires Labcorp to maintain a consolidated leverage ratio not exceeding 4.0 to 1.0, with the ability to increase this to 4.5 to 1.0 for four quarters in connection with a material acquisition under a defined “Leverage Holiday” framework.
LABCORP HOLDINGS INC. President & CEO Adam H. Schechter sold 8,705 shares of common stock in an open-market transaction on March 3, 2026 at an average price of $279.9595 per share. After this sale, he directly owned 80,773 shares of Labcorp common stock.